1Elizabeth V L, Grgacic, David A. Anderson. Virus-like particles: Passport to immune recognition [J]. Methods, 2006, 40: 60-65.
2Sarah E B, Kelly L W, Christine M O'Neal, et al. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs) [J]. Vaccine, 2006, 24:1170-1179.
3Margaret Stanley, Douglas R Lowy, Ian Frazer. Prophylactic HPV vaccines: Underlying mechanisms[J]. Vaccine, 2006, 24: 106-113.
4Robert L Garcea, Lutz Gissmann. Virus-like particles as vaccines and vessels for the delivery of small molecules[J]. Current Opinion in Biotechnology, 2004, 15: 513-517.
5Laura A K, Diane M H. Current findings from prophylactic HPV vaccine trials[J]. Vaccine, 2006, 24: 114-121.
6Luisa L V, Kevin A A, Anna R G,et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6,11,16, and 18 [J]. Vaccine, 2006, 24:5571-5583.
7Christophe F, Joanne E T, Liwen Xi, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) viruslike panicle (VLP) type 16 prophylactic[J]. Vaccine, 2007, 2: 69-78.
8Ligia A P, Raphael V, Clayton D H,et al. Cellular immune responses to HPV-18, -31, and-53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles[J]. Virology, 2006, 353: 451-462.
9Yu-Kyoung Oh, Taejong Sohn, Jeong-Sook Park, et al. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant [J]. Virology, 2004, 328:266-273.
10Katharina S, Ratish G, Timothy D C, et al. A papillomaviruslike particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11[J]. Vaccine, 2007, 25:2001-2010.